Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as cema-cel
cemacabtagene ansegedleucel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| cemacabtagene ansegedleucel | EXPERIMENTAL | Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide. |
| Observation | OTHER | Participants do not receive any study treatments. They are observed as per the current standard of care. |
| Name | Type | Description |
|---|---|---|
| cemacabtagene ansegedleucel | GENETIC | An allogeneic CAR T cell therapy targeting CD19 |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
| Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ | DEVICE | A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for LBCL. |
Key Inclusion Criteria: 1. LBCL per WHO 2017 including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and primary mediastinal B-cell lymphoma histologically confirmed by pathology report. 2. Participant has completed a full course of standard first line therapy (e.g., R-CHOP, dose-adjus...
Cemacabtagene ansegedleucel is an investigational CAR-T cell therapy being studied in large B-cell lymphoma. It is being evaluated as consolidation treatment for patients who achieve a first-line remission but remain positive for minimal residual disease, meaning low levels of cancer cells are still detectable after initial therapy.
Cemacabtagene ansegedleucel targets CD19, a protein found on the surface of B cells and on most large B-cell lymphoma cells. It is a CAR-T therapy, meaning the patient's own T cells are engineered to recognize and attack cells expressing CD19.
Cemacabtagene ansegedleucel is being developed by Allogene Therapeutics, Inc., which trades on the Nasdaq under the ticker ALLO. The company is running the clinical program for the drug in large B-cell lymphoma.
Cemacabtagene ansegedleucel is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. The FDA has granted it Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations.
Cemacabtagene ansegedleucel is being studied in the Phase 2 trial NCT06500273, titled Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL. The trial is recruiting approximately 250 adults with large B-cell lymphoma across the United States, Australia, Canada, and South Korea.
Yes, cema-cel is a shorthand name for cemacabtagene ansegedleucel. Both names refer to the same investigational CD19-directed CAR-T cell therapy being developed by Allogene Therapeutics for large B-cell lymphoma.